Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company’s robust late-stage pipeline could offset ...

Cancer treatments can instigate ocular surface disease and other deleterious ocular side effects that optometrists can oversee and manage.

The article " 3 Biopharmaceutical Stocks Bucking the Sell-Off " first appeared on MarketBeat.

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

The financial terms of the deal were not disclosed, but TigaTx will become a wholly owned subsidiary of Epsilogen as part of ...

UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.

Truist analyst Joon Lee raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $76 and keeps a Buy rating on the shares.